Pharming Group N.V. ADR (PHAR)

$8.80 -0.04 (-0.45%)
Market Cap 602.38M
Revenue (ttm) 245.32M
Net Income (ttm) -10.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 270.00
Profit Margin -4.30%
Debt to Equity Ratio 0.01
Volume 2,900
Avg Vol 6,924
Day's Range N/A - N/A
Shares Out 67.84M
Stochastic %K 23%
Beta -0.08
Analysts Strong Sell
Price Target $27.00

Latest News on PHAR

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 12:00 PM EST - 9 days ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Jan 21, 2025, 1:00 AM EST - 9 days ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 15, 2024, 1:45 PM EST - 6 weeks ago

Pharming announces public cash offer to the shareholders of Abliva AB

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Dec 11, 2024, 9:34 AM EST - 7 weeks ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Pharming Group to participate in November investor conference

Nov 5, 2024, 2:00 AM EST - 3 months ago

Pharming Group to participate in November investor conference

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:44 PM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 2:00 AM EDT - 4 months ago

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Oct 10, 2024, 1:00 AM EDT - 4 months ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 26, 2024, 1:00 AM EDT - 4 months ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming Group to participate in September investor conferences

Sep 4, 2024, 1:00 AM EDT - 5 months ago

Pharming Group to participate in September investor conferences

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 3:26 PM EDT - 6 months ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Aug 1, 2024, 1:00 AM EDT - 6 months ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Pharming Group to report second quarter and first half 2024 financial results on August 1

Jul 18, 2024, 2:00 AM EDT - 7 months ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

Pharming Group to participate in June investor conferences

Jun 3, 2024, 2:00 AM EDT - 8 months ago

Pharming Group to participate in June investor conferences

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 30, 2024, 4:44 PM EDT - 8 months ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 21, 2024, 11:30 AM EDT - 9 months ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Pharming Group to participate in May investor conference

May 20, 2024, 2:00 AM EDT - 9 months ago

Pharming Group to participate in May investor conference

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 15, 2024, 1:00 AM EDT - 9 months ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

May 12, 2024, 9:19 AM EDT - 9 months ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 2:00 AM EDT - 10 months ago

Pharming Group to report first quarter 2024 financial results on May 8

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 24, 2024, 1:00 AM EDT - 10 months ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 19, 2024, 12:43 PM EDT - 10 months ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 9:04 AM EDT - 10 months ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 2:00 AM EDT - 10 months ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 8, 2024, 1:00 AM EDT - 10 months ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 2:30 AM EDT - 10 months ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Apr 4, 2024, 1:00 AM EDT - 10 months ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 1:15 PM EDT - 11 months ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Pharming Group reports fourth quarter and full year 2023 financial results

Mar 14, 2024, 2:00 AM EDT - 11 months ago

Pharming Group reports fourth quarter and full year 2023 financial results

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Feb 29, 2024, 2:00 AM EST - 1 year ago

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Pharming Group to participate in February investor conferences

Feb 8, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in February investor conferences

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Jan 8, 2024, 1:00 AM EST - 1 year ago

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Dec 13, 2023, 1:00 AM EST - 1 year ago

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Nov 10, 2023, 8:51 AM EST - 1 year ago

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Nov 7, 2023, 2:00 AM EST - 1 year ago

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Pharming Group to participate in November investor conferences

Nov 1, 2023, 3:00 AM EDT - 1 year ago

Pharming Group to participate in November investor conferences

Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript

Oct 27, 2023, 8:35 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript

Pharming Group N.V. (PHGUF) Q3 2023 Earnings Call Transcript

Oct 26, 2023, 10:33 PM EDT - 1 year ago

Pharming Group N.V. (PHGUF) Q3 2023 Earnings Call Transcript

Pharming Group reports third quarter 2023 financial results

Oct 26, 2023, 1:00 AM EDT - 1 year ago

Pharming Group reports third quarter 2023 financial results

Pharming Group to report third quarter 2023 financial results on October 26

Oct 12, 2023, 2:00 AM EDT - 1 year ago

Pharming Group to report third quarter 2023 financial results on October 26

Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

Sep 25, 2023, 10:00 AM EDT - 1 year ago

Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation

Sep 9, 2023, 12:30 PM EDT - 1 year ago

Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

Aug 9, 2023, 1:00 AM EDT - 1 year ago

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript

Aug 6, 2023, 4:51 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript

Pharming Group N.V. (PHGUF) Q2 2023 Earnings Call Transcript

Aug 6, 2023, 2:54 AM EDT - 1 year ago

Pharming Group N.V. (PHGUF) Q2 2023 Earnings Call Transcript

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Jul 18, 2023, 1:00 AM EDT - 1 year ago

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Pharming Group to report second quarter and first half 2023 financial results on August 3

Jul 13, 2023, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2023 financial results on August 3

Pharming announces sale of priority review voucher

Jun 1, 2023, 1:00 AM EDT - 1 year ago

Pharming announces sale of priority review voucher

Pharming Group to attend the following Investor Conferences in June

May 25, 2023, 2:00 AM EDT - 1 year ago

Pharming Group to attend the following Investor Conferences in June

Pharming Group N.V. (PHGUF) Q1 2023 Earnings Call Transcript

May 11, 2023, 2:44 PM EDT - 1 year ago

Pharming Group N.V. (PHGUF) Q1 2023 Earnings Call Transcript